Waverunner
Senior Member
- Messages
- 1,079
Could be relevant for the inflammatory parts of CFS.
http://detroit.cbslocal.com/2012/09...rriers-to-treat-cancer-inflammatory-diseases/
DETROIT — A Wayne State University research team in the Eugene Applebaum College of Pharmacy and Health Sciences has developed a novel approach to the design of nanocarriers for treatment of metastatic cancer and inflammatory diseases.
Published in the prestigious international chemistry journal Angewandte Chemie, the study “Dual-function CXCR4 Antagonist Polyplexes to Deliver Gene Therapy and Inhibit Cancer Cell Invasion” introduces a new type of nanocarriers that have unique dual functionality.
“The nanocarriers not only limit metastasis and inflammation, but also deliver additional therapeutic agents with anticancer or anti-inflammatory activity,” said associate professor David Oupicky, who heads the research team in the college’s department of pharmaceutical sciences.
In describing the design, Oupicky said, “Published reports suggest that certain drugs, called CXCR4 antagonists, can limit tumor growth and metastasis in various cancers. This makes the CXCR4 receptor a suitable target for the development of combination nanocarriers that control cancer metastasis and can deliver a second knock-out punch.”
...
http://detroit.cbslocal.com/2012/09...rriers-to-treat-cancer-inflammatory-diseases/
DETROIT — A Wayne State University research team in the Eugene Applebaum College of Pharmacy and Health Sciences has developed a novel approach to the design of nanocarriers for treatment of metastatic cancer and inflammatory diseases.
Published in the prestigious international chemistry journal Angewandte Chemie, the study “Dual-function CXCR4 Antagonist Polyplexes to Deliver Gene Therapy and Inhibit Cancer Cell Invasion” introduces a new type of nanocarriers that have unique dual functionality.
“The nanocarriers not only limit metastasis and inflammation, but also deliver additional therapeutic agents with anticancer or anti-inflammatory activity,” said associate professor David Oupicky, who heads the research team in the college’s department of pharmaceutical sciences.
In describing the design, Oupicky said, “Published reports suggest that certain drugs, called CXCR4 antagonists, can limit tumor growth and metastasis in various cancers. This makes the CXCR4 receptor a suitable target for the development of combination nanocarriers that control cancer metastasis and can deliver a second knock-out punch.”
...